Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis
Cardiorenal Medicine · 16.09.2024 · 14 (1) · 570-580
DOI: 10.1159/000541393 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiorenal Medicine, online erschienen am 16.09.2024. Verfasst von Carlo Lavalle und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Aminobutyrates, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
The efficacy and safety of emerging therapies for heart failure with reduced ejection fraction (HFrEF) have never been compared in specific subgroups of patients.
Methods
PubMed, Cochrane Registry, Web of Science, Scopus, and EMBASE libraries were used to extract data. We used the following keywords: (heart failure with reduced ejection fraction OR HFrEF) AND (treatment OR therapy) OR (cardiovascular death) OR (hospitalization for heart failure). We compared randomized clinical trials for HFrEF emerging therapies focusing on the elderly (patients >65 years old and >75 years old), chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) < 60 mL/min), patients with diabetes mellitus (DM), coronary heart disease (CAD), New York Heart Association (NYHA) class III/IV, women, patients on sacubitril/valsartan (S/V). The primary outcome was the efficacy composite endpoint of cardiovascular death (CVD) and HF hospitalization (HFH).
Results
S/V significantly reduced the primary outcome in patients >65 years old (RR: 0.80; 95% CI: 0.68–0.94) and with CKD (RR: 0.79; 95% CI: 0.69–0.90); dapagliflozin in patients >65 (RR: 0.72; 95% CI: 0.60–0.86) and >75 years old (RR: 0.68; 95% CI: 0.53–0.87), in those with CKD (RR: 0.72; 95% CI: 0.59–0.88), DM (RR: 0.75; 95% CI: 0.63–0.89), and CAD (RR: 0.77; 95% CI: 0.65–0.92); empagliflozin in patients >65 years old (RR: 0.78; 95% CI: 0.66–0.93), those with DM (RR: 0.72; 95% CI: 0.60–0.86), CAD (RR: 0.82; 95% CI: 0.68–0.99), women (RR: 0.59; 95% CI: 0.44–0.79), and in patients on S/V (RR: 0.64; 95% CI: 0.45–0.91); vericiguat in patients with CKD (RR: 0.84; 95% CI: 0.73–0.97) and NYHA class III/IV (RR: 0.87; 95% CI: 0.77–0.98); omecamtiv mecarbil in patients with CAD (RR: 0.90; 95% CI: 0.82–0.99) and NYHA III/IV (RR: 0.88; 95% CI: 0.80–0.97).
Conclusion
Emerging HFrEF therapies show a clinical benefit with the reduction of the primary composite endpoint of CVD and HFH, with each drug being more effective in specific patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical, Internal, Anesthesiologist and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
- Department of Nephrology and Dialysis, Azienda USL Roma 6, Rome, Italy.
- Department of Cardiology, S. Eugenio Hospital, Rome, Italy.
- Department of Nephrology and Dialysis, International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy.
Zitieren
APA
Lavalle, C., Mariani, M. V., Severino, P., Palombi, M., Trivigno, S., D'Amato, A., Silvetti, G., Pierucci, N., Di Lullo, L., Chimenti, C., Summaria, F., Ronco, C., Badagliacca, R., Miraldi, F., & Vizza, C. D. (2024). Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis. Cardiorenal Medicine, 14(1), 570-580. https://doi.org/10.1159/000541393
Vancouver
Lavalle C, Mariani MV, Severino P, Palombi M, Trivigno S, D'Amato A, et al. Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis. Cardiorenal Medicine. 2024;14(1):570-580. doi:10.1159/000541393
BibTeX
@article{Lavalle2024,
author = {Lavalle, Carlo and Mariani, Marco Valerio and Severino, Paolo and Palombi, Marta and Trivigno, Sara and D'Amato, Andrea and Silvetti, Giacomo and Pierucci, Nicola and Di Lullo, Luca and Chimenti, Cristina and Summaria, Francesco and Ronco, Claudio and Badagliacca, Roberto and Miraldi, Fabio and Vizza, Carmine Dario},
title = {Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis},
journal = {Cardiorenal Medicine},
year = {2024},
volume = {14},
number = {1},
pages = {570--580},
doi = {10.1159/000541393}
}
EUVIMED